Matthew Posard

Matthew L.
Posard is currently Chairman at DermTech, Inc. since 2016, Executive Chairman at Stemson Therapeutics, LLC since 2019, Chairman at Nautilus Subsidiary, Inc. since 2018, Chairman at Nautilus Biotechnology, Inc. since 2021, Independent Director at Halozyme Therapeutics, Inc. since 2013, Director at Isolation Bio, Inc. since 2020, Director at Deepcell, Inc. since 2022, Independent Director at Talis Biomedical Corp.
since 2016, Director at Vizgen, Inc. since 2021, and Partner at Explore DNA since 2015.
Former roles include Chairman at DermTech Operations, Inc. in 2019, Regional Director-Sales at Alere San Diego, Inc., Director at SlipChip Corp., Director at Fabric Genomics, Inc. from 2016 to 2019, Senior Vice President and GM-New & Emerging Markets at Illumina, Inc. from 2014 to 2015, Senior Manager-Strategic Marketing at Gen-Probe, Inc., Chief Commercial Officer and Executive VP at Cardiff Oncology, Inc. from 2015 to 2016, and President and Chief Commercial Officer at GenePeeks, Inc. from 2017 to 2018.
Education includes undergraduate studies at the University of California San Diego.